Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;59(1):61-65.
doi: 10.4111/icu.2018.59.1.61. Epub 2017 Dec 21.

Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions

Ethan L Matz  1 , Amy M Pearlman  1 , Ryan P Terlecki  1
Affiliations

Safety and feasibility of platelet rich fibrin matrix injections for treatment of common urologic conditions

Ethan L Matz et al. Investig Clin Urol. 2018 Jan.

Abstract

Purpose: Autologous platelet rich plasma (PRP) is used increasingly in a variety of settings. PRP injections have been used for decades to improve angiogenesis and wound healing. They have also been offered commercially in urology with little to no data on safety or efficacy. PRP could theoretically improve multiple urologic conditions, such as erectile dysfunction (ED), Peyronie's disease (PD), and stress urinary incontinence (SUI). A concern with PRP, however, is early washout, a situation potentially avoided by conversion to platelet rich fibrin matrix (PRFM). Before clinical trials can be performed, safety analysis is desirable. We reviewed an initial series of patients receiving PRFM for urologic pathology to assess safety and feasibility.

Materials and methods: Data were reviewed for patients treated with PRFM at our center from November 2012 to July 2017. Patients were observed immediately post-injection and at follow-up for complications and tolerability. Where applicable, International Index of Erectile Function (IIEF-5) scores were reviewed before and after injections for ED and/or PD. Pad use data was collected pre/post injection for SUI.

Results: Seventeen patients were identified, with a mean receipt of 2.1 injections per patient. Post-procedural minor adverse events were seen in 3 men, consisting of mild pain at injection site and mild penile bruising. No patients experienced complications at follow-up. No decline was observed in men completing pre/post IIEF-5 evaluations.

Conclusions: PRFM appears to be a safe and feasible treatment modality in patients with urologic disease. Further placebo-controlled trials are warranted.

Keywords: Erectile dysfunction; Penile induration; Platelet-rich fibrin; Platelet-rich plasma; Urinary incontinence, stress.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: The authors have nothing to disclose.

Comment in

References

    1. Andia I, Maffulli N. Platelet-rich plasma for managing pain and inflammation in osteoarthritis. Nat Rev Rheumatol. 2013;9:721–730. - PubMed
    1. Jiritano F, Serraino GF, Rossi M, Dominijanni A, Brescia A, Renzulli A. Ventricular assist device driveline infection: treatment with platelet-rich plasma. Ann Thorac Surg. 2013;96:e37–e38. - PubMed
    1. Marck RE, Middelkoop E, Breederveld RS. Considerations on the use of platelet-rich plasma, specifically for burn treatment. J Burn Care Res. 2014;35:219–227. - PubMed
    1. Schiavone G, Raskovic D, Greco J, Abeni D. Platelet-rich plasma for androgenetic alopecia: a pilot study. Dermatol Surg. 2014;40:1010–1019. - PubMed
    1. Zhou B, Ren J, Ding C, Wu Y, Chen J, Wang G, et al. Protection of colonic anastomosis with platelet-rich plasma gel in the open abdomen. Injury. 2014;45:864–868. - PubMed

Publication types